Advertisment
 

Join the Topix community today: 

Sign Up

 | 

Sign In

Wyeth Wire

Comprehensive News Feed for Wyeth.

Results 1 - 20 of 600 in Wyeth

  1. Wyeth shares rises on promising study of Alzheimer's drugRead the original story

    12 hrs ago | International Herald Tribune

    The drug maker Wyeth said Tuesday that an investigational product for treating Alzheimer's showed promise in an intermediate clinical study.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  2. Wyeth, Progenics Drug Clears ECRead the original story

    Friday Jul 4 | Contract Pharma Breaking News

    ... treatment for opioid-induced constipation (OIC), has been approved by the European Commission. The drug, developed by Wyeth and Progenics , is now approved in the 27 member states of the European Union as well as Iceland, Norway, and Liechtenstein. ...

    Comment?

    Related Topix: Biotech, Healthcare Industry, Progenics Pharmaceuticals

  3. Wyeth and Progenics announces receipt of approval from European...Read the original story

    Friday Jul 4 | M2.com

    Wyeth and Progenics announces receipt of approval from European Commission of RELISTOR as a treatment for OIC Published in M2 EquityBites on Friday, 04 July 2008 at 13:19 GMT Wyeth Pharmaceuticals, a provider ...

    Comment?

    Related Topix: Biotech, Healthcare Industry, Progenics Pharmaceuticals, Women's Health, Health, Marketing

  4. Wyeth and Progenics Receive Approval from European Commission for...

    Friday Jul 4 | AndhraNews

    Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc.

    Comment?

    Related Topix: Marketing, Biotech, Medicine, Healthcare Industry, Progenics Pharmaceuticals, Palliative Care

  5. Wyeth Pharmaceuticals-Progenics drug Relistor OK'd in EuropeRead the original story

    Monday Jun 30 | Philadelphia Business Journal

    Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc. received marketing approval from the European Commission Thursday for Relistor, a treatment of opioid-induced constipation in advanced illness patients ...

    Comment?

    Related Topix: Biotech, Healthcare Industry, Progenics Pharmaceuticals

  6. Myriad's Small Billion-Dollar LossRead the original story

    Tuesday Jul 1 | Fool.com

    ... large market potential for drugs with even modest efficacy effects, it is understandable why a company like Myriad or Wyeth (NYSE: WYE ) and Elan (NYSE: ELN ) would bring these compounds into phase 3 testing with less than unblemished data from ...

    Comment?

    Related Topix: Biotech, Medicine, Myriad Genetics, Healthcare Industry, Alzheimer's, Health

  7. FDA News Gives Glaxo a Glimmer of HopeRead the original story

    Tuesday Jul 1 | Motley Fool

    ... Gardasil has recently seen FDA setbacks of its own. Vaccines are the bedrock supporting multiple drugmakers, including Wyeth (NYSE: WYE ) and Sanofi-Aventis (NYSE: SNY ) . While it's unfortunate for Glaxo that it will have to wait until at least ...

    Comment?

    Related Topix: Biotech, GlaxoSmithKline, Food and Drug Administration, Healthcare Law, Law

  8. Drug trial defies Wall Street's 'wisdom'

    Tuesday Jul 1 | MSN Money

    ... offer hope to millions of Alzheimer's patients. When the market opened Tuesday, both Elan ( ELN , news , msgs ) and Wyeth ( WYE , news , msgs ) traded up as much as 7% as the results of their Phase II trial for AAB-001 hit the newswires. Then ...

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry, Alzheimer's, Health, Elan Corporation Plc

  9. Alzheimer's Failure For Myriad GeneticsRead the original story

    Monday Jun 30 | Forbes.com

    ... further outperforms expectations." Myriad shares rose in mid-June after Elan (nyse: ELN - news - people ) and Wyeth (nyse: WYE - news - people ) reported positive results for their Alzheimer's drug candidate, bapineuzumab (See " Elan and Wyeth ...

    Comment?

    Related Topix: Salt Lake City Metro, Salt Lake City, UT, Alzheimer's, Health, Biotech, Medicine, Myriad Genetics, Healthcare Industry

  10. Wyeth Sets Webcast and Conference Call for 2008 Second Quarter EarningsRead the original story

    Monday Jun 30 | PR Newswire

    On Wednesday, July 23, 2008, Wyeth will announce financial results for the 2008 second quarter.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  11. Monday Options Update: C, MYGN, TSN, LLTC, F, GM, BEC, RNWKRead the original story

    Monday Jun 30 | The US Market Blog

    ... treating symptoms of the disease), and after promising clinical results for similar drugs from Elan Corp ( ELN ) and Wyeth ( WYE ) earlier this month, the market was looking for validation of the anti-amyloid therapeutic concept with Myriad's ...

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry, Myriad Genetics, CPU, Science / Technology

  12. Health-Care Funds Are Ailing in 2008Read the original story

    Friday Jun 27 | SmartMoney.com

    ... of 143 companies, including Johnson & Johnson ( JNJ ), Pfizer ( PFE ), Abbott Laboratories ( ABT ), Merck ( MRK ) and Wyeth ( WYE ). The fund charges a cheap $48 for every $10,000 invested. Any time an investor is dealing with a sector it probably ...

    Comment?

    Related Topix: Financial Markets

  13. Wyeth shares rises on promising study of Alzheimer's drugRead the original story

    Friday Jun 27 | International Herald Tribune

    The drug maker Wyeth said Tuesday that an investigational product for treating Alzheimer's showed promise in an intermediate clinical study.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  14. Wyeth CEO Poussot takes chairman seatRead the original story

    Friday Jun 27 | Millville News

    Madison drug-maker Wyeth announced that Bernard Poussot, its president and CEO, will take on the additional role of chairman, effective immediately.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  15. Wyeth Announces Bernard Poussot Assumes Chairman of the Board PositionRead the original story

    Friday Jun 27 | PR Newswire

    Wyeth has announced that Bernard Poussot, 56, Wyeth's President and Chief Executive Officer, has assumed the additional position of Chairman of the Board, effective today.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  16. Wyeth CEO Bernard Poussot takes on chairman roleRead the original story

    Friday Jun 27 | International Business Times

    Drug maker Wyeth said Friday President and Chief Executive Bernard Poussot will take on the added role of chairman, effective immediately.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  17. Wyeth Declares Common and Preferred Stock DividendsRead the original story

    Thursday Jun 26 | PR Newswire

    At a meeting of its Board of Directors, held today, Wyeth declared dividends on both the Common and Preferred Stock of the Company.

    Comment?

    Related Topix: Biotech, Medicine, Healthcare Industry

  18. Northern Trust Casts NETS Over Celtic TigerRead the original story

    Tuesday Jun 24 | Investor's Business Daily

    ... pattern on June 17. The stock soared last week on news that a new Alzheimer's drug, in development with Wyeth , ( WYE ) helped a large patient test group. Macro Picture The ISEQ 20 Index has fallen 25% year to date, as of Tuesday. It has lost 46% in ...

    Comment?

    Related Topix: Financial Markets, Allied Irish Banks plc, Financial Services, Governor and Company of the Bank of Ireland, Biotech, Elan Corporation Plc, Opinion

  19. More Than Momentum: Stocks Rising for a ReasonRead the original story

    Tuesday Jun 24 | Motley Fool

    ... Elan has been trending up after a preview of some results from tests of its mid-stage Alzheimer's drug with partner Wyeth (NYSE: WYE ) last week. Some analysts concluded that the drug appears to help treat a large percentage of patients with the ...

    Comment?

    Related Topix: Semiconductors, Evergreen Solar, Electronics, Financial Markets

  20. Elan, Wyeth: Response to Skeptics on Alzheimer's DataRead the original story

    Thursday Jun 19 | The Biotech Stock Blog

    Elan and Wyeth presented their phase II data on June 17th with bapineuzumab in Alzheimer's Disease.

    Comment?

    Related Topix: Alzheimer's, Health, Biotech, Medicine, Healthcare Industry, Elan Corporation Plc